CN1020406C - Process for preparing chronic atrophic gastritis medicine - Google Patents
Process for preparing chronic atrophic gastritis medicine Download PDFInfo
- Publication number
- CN1020406C CN1020406C CN 89101311 CN89101311A CN1020406C CN 1020406 C CN1020406 C CN 1020406C CN 89101311 CN89101311 CN 89101311 CN 89101311 A CN89101311 A CN 89101311A CN 1020406 C CN1020406 C CN 1020406C
- Authority
- CN
- China
- Prior art keywords
- atrophic gastritis
- medicine
- chronic atrophic
- fructus jujubae
- herba chelidonii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a method for preparing a capsule preparation of traditional Chinese medicine for treating chronic atrophic gastritis, which is formed by manufacture of celandine and Chinese date according to a certain recipe and an operation technology. The medicine has the advantages of convenient manufacture method, convenient administration, easy clinic repeat, obvious effect, good curative effect and no side effect. The present invention is the ideal medicine for treating chronic atrophic gastritis and preventing and curing gastric cancer.
Description
The present invention relates to a kind of manufacture method and quality standard that is used for the treatment of the Chinese medicinal capsule preparation of chronic atrophic gastritis.IPC：A61K。
Chronic atrophic gastritis is a kind of common and chronic disease of refractory, and sickness rate is more and more high with advancing age, and often with dysplasia and intestinalization.Atrophic gastritis with in～then be called gastric precancerous lesion during severe dysplasia, so gastric cancer can take place small number of patients, still do not have satisfied therapy so far.
The clinical efficacy of the traditional Chinese medical science and therapy of combining Chinese and Western medicine chronic atrophic gastritis is 87～97.1% in recent years, and the pathology curative effect is 63.6%.But method of syndrome differentiation is difficult for grasping, and flavour of a drug are many, and decoction is taken inconvenience, also is difficult for the further mechanism of research curative effect.The medicine of the treatment chronic atrophic gastritis that the present invention makes needn't be dialectical again, and flavour of a drug are few, and the capsule taking convenience is easy to clinical repetition, and the foundation of modern toxicity, pharmacology and medicine experiment is arranged, and is convenient to promote and further investigation.The invention provides the medicine production method of a kind of easy, effective, the non-evident effect of treatment chronic gastritis, the method there is no report both at home and abroad.
The medicine that the present invention makes is applicable to the patient of various chronic atrophic gastritis, and is especially better with spleen-stomach deficiency-cold, due to weakness of spleen and stomach, spleen liver depression-type.This medicine has warming and invigorating the spleen and stomach, eliminating inflammation and expelling toxin, the function of the relieving distension that relieves the pain, stimulating appetite, improvement sleep.Main treatment chronic atrophic gastritis, and gastric precancerous lesion also had curative effect preferably is a kind of treatment chronic atrophic gastritis and prevent and treat the comparatively ideal medicine of gastric cancer.By systematic treating chronic atrophic gastritis 102 examples, clinical total effective rate is 96.1%, and the gastroscope total effective rate is 52.9%, and the pathology total effective rate is 58.8%.Total effective rate to the dysplasia relevant with gastric cancer is 76.6%, and the total effective rate of intestinal epithelial metaplasia is 54.9%.
Manufacture method of the present invention is as follows:
1, prescription:
Herba Chelidonii 750 grams
Fructus Jujubae 750 grams
Make 1000 of capsules altogether.
2, preparation technology:
Get the cutting of Herba Chelidonii herb, mix with Fructus Jujubae, water decocts twice.For the first time amount of water is Herba Chelidonii and Fructus Jujubae gross weight 7 times, and heated and boiled 1 hour filters, and collects filtrate.Crude drug is decocted with water for the second time, amount of water is Herba Chelidonii and Fructus Jujubae gross weight 5 times again, heated and boiled half an hour, filters.To be concentrated into the thick paste shape after twice filtrate merging.Rebasing with starch, 70 ℃～80 ℃ heat dryings grind into fine powder.Adjust explosive payload by the prescription regulation, incapsulate promptly.
Through medicineization, pharmacological research, the Fructus Jujubae of using in the manufacturing of the present invention contains nine seed amino acids such as lysine, aspartic acid, glycine, agedoite, glutamic acid, alanine, proline, valine and leucine.Contain D-fructose 0.8%, D-glucose 32.5%, sucrose 8.8%, oligosaccharide 13.0%(glucose and fructose in the Fructus Jujubae extract), six kinds of saccharides such as araban 0.3%, galactose polyacetals polysaccharide 0.3%, also contain 36 kinds of trace element such as four kinds of vitamin such as ascorbic acid, Citrin, A, B2 and potassium, ferrum, manganese, calcium.These materials have good Nutrition to the gastric mucosa of atrophy, and vitamin B2 and A are more beneficial to treatment atrophic gastritis and gastric cancer.Fructus Jujubae can increase total serum protein and albumin, and the effect of anticancer propagation is arranged.Also have antiallergic action and central nerve inhibition effect in addition, and calmness, syngignoscism are arranged.Herba Chelidonii in this medicine contains 19 kinds of alkaloids such as Chelidonine, protopine, coptisine, and wherein Chelidonine is the Main Ingredients and Appearance of Herba Chelidonii total alkali, accounts for 40%.Chelidonine has inhibitory action to phosphodiesterase, can stop CAMP to change 5 ' AMP into, thereby keeps the higher concentration of CAMP.CAMP content has the proliferation of cells of inhibition and differentiation when increasing, add CAMP in stripped cancerous cell culture fluid, the growth of energy anticancer, even recover normal cell.Chronic atrophic gastritis Deficiency and coldness of spleen and stomach stagnation of QI person, gastric mucosa CAMP content reduces, and with gastric cancer certain relation is arranged.With Herba Chelidonii and Fructus Jujubae preparation for treating, antiinflammatory on the one hand, pain relieving, relieving distension, invigorating spleen and reinforcing stomach, the inflammation of gastric mucosa and the body of gland of atrophy are recovered gradually, increase CAMP content in gastric mucosa and the blood plasma on the other hand, the generation of blocking-up canceration, moreover Fructus Jujubae itself has the effect of anticancer propagation again, provides the physics and chemistry basis for selecting this two flavor medicine treatments chronic atrophic gastritis for use.
The quality standard of this medicine is as follows:
The dry extract that every of this medicine contains Herba Chelidonii, Fructus Jujubae is equivalent to each 0.75 gram of crude drug in whole.
(discriminating) gets dry extract 10 grams in this product capsule, add 50 milliliter of 1% sulfuric acid solution dissolving, filter settled solution, add 20% sodium hydroxide and transfer about PH to 9, extracted 5 minutes, get chloroform extracted solution with 50 milliliters of chloroform joltings, after dechlorination is imitative, chloroform extract adds 10 milliliter of 0.5% sulphuric acid dissolve with ethanol, filters, and filtrate is done following analysis and used:
1, gets 1 milliliter of filtrate, add bismuth potassium iodide test solution: salmon precipitation promptly takes place.
2, get 1 of filtrate, point is put irradiation observation under the ultraviolet light 254nm wavelength on filter paper, present the yellow-greenish phosphorescent light point.
3, get filtrate and put on the silica gel G thin layer, developing solvent is a dimethylbenzene: methanol (9: 1) launches the back at λ=293nm place, and the Chelidonine maximum absorption band is arranged, under uv analyzer 254nm, forsythia fluorescence speckle is arranged, and Chelidonine Rf=0.42 should be consistent with the reference substance collection of illustrative plates.
(inspection method) done by the regulation of 7 pages of capsule items of Chinese Pharmacopoeia two appendix of in 1985 version.
(assay) Chelidonine is measured: take by weighing sample 10 grams, adding 100 milliliters of joltings of 0.5% sulphuric acid ethanol extracts 2 times, each 2 hours, filter, merging filtrate, after boiling off ethanol, be dissolved in water, transfer PH to 9 with 15% sodium hydroxide solution, with chloroform extraction 3 times, boil off chloroform, filter, be settled to 10 milliliters with anhydrous alcohol solution, extracting sample solution and Chelidonine standard solution are put respectively on the silica gel G thin layer, with dimethylbenzene: methanol (9: 1) launches, and is positioned at λ=293nm place and measures the speck area integrated value with the quick thin-layer chromatogram scanner of CS-920 under uv analyzer 254nm, calculating content.
Sample Chelidonine content=(the every ml concentration of sample point area integral value * standard substance * point sample amount)/(standard sample speck area integrated value * sample point sample amount)
The Herba Chelidonii alkali number must not be less than 1 μ g/10mg in this medicine.
(usage and consumption) is oral, and one day three times, each 4～5, taking medicine before meal is used.
Claims (1)
- A kind of is the manufacture method of the Chinese medicinal capsule preparation of feedstock production treatment chronic atrophic gastritis with Herba Chelidonii, Fructus Jujubae, it is characterized in that this method comprises the following steps:(1) get the cutting of Herba Chelidonii herb, mix with the Fructus Jujubae of identical weight, the water heated and boiled that adding Herba Chelidonii and Fructus Jujubae gross weight are 7 times 1 hour filters, and collects filtrate;(2) again with the water heated and boiled half an hour of 5 times of weight of crude drug adding, filter;(3) will be concentrated into paste after twice filtrate merging, rebasing with starch, 70 ℃ of-80 ℃ of heat dryings grind into fine powder and incapsulate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 89101311 CN1020406C (en) | 1989-03-10 | 1989-03-10 | Process for preparing chronic atrophic gastritis medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 89101311 CN1020406C (en) | 1989-03-10 | 1989-03-10 | Process for preparing chronic atrophic gastritis medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1045351A CN1045351A (en) | 1990-09-19 |
| CN1020406C true CN1020406C (en) | 1993-05-05 |
Family
ID=4854226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 89101311 Expired - Fee Related CN1020406C (en) | 1989-03-10 | 1989-03-10 | Process for preparing chronic atrophic gastritis medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1020406C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327877C (en) * | 2004-08-19 | 2007-07-25 | 上海雷允上药业有限公司 | Compound Chinese medicinal formulation for treating chronic atrophic gastritis and its preparing method |
| CN102357239B (en) * | 2011-10-27 | 2013-02-13 | 迟荣 | Chinese medicine composition for treating chronic atrophic gastritis |
| CN107158302B (en) * | 2017-05-22 | 2021-02-02 | 南京中科药业有限公司 | A natural pharmaceutical composition for protecting gastric mucosa, and its preparation method |
| CN115040521B (en) * | 2022-05-10 | 2023-09-22 | 金陵科技学院 | Application of B-vitamin and butyrate composition in preparation of medicines for killing gastric cancer cells |
-
1989
- 1989-03-10 CN CN 89101311 patent/CN1020406C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1045351A (en) | 1990-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singhuber et al. | Aconitum in traditional Chinese medicine—a valuable drug or an unpredictable risk? | |
| CN101757591B (en) | Traditional Chinese medicine composition for treating chronic colitis and protitis | |
| CN101167863B (en) | Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof | |
| CN104491342A (en) | Medicament for treating diabetes and preparation method thereof | |
| CN1020406C (en) | Process for preparing chronic atrophic gastritis medicine | |
| CN101020016B (en) | Medicine for treating fracture and injured tendon and its preparation | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN101327293B (en) | Capsules for treating peptic ulcer and preparation method thereof | |
| CN101336965A (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN105169189B (en) | A kind of drug treated first and subtracted | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN100467043C (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN1192789C (en) | 'Shenhuaxiaokecha' tea and preparing method thereof | |
| CN1280010A (en) | Oral medicine for treating diabetes and its production method | |
| CN100484561C (en) | Medicament composition for treating ulcer in alimentary canal and preparation method | |
| CN105169187B (en) | A kind of composition and its application, preparation method and drug, food containing the composition | |
| CN102579801B (en) | Traditional Chinese medicine preparation for treating diabetic syndrome and preparation method of same | |
| CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
| CN100462081C (en) | Novel medical uses of perennial sowthistle and preparing method for intermediate thereof | |
| CN101485845A (en) | Chinese medicine for treating diabetes | |
| CN101264202B (en) | Hericium erinaceus digestion-promoting Chinese medicinal composition and preparation thereof | |
| CN100560087C (en) | Pharmaceutical composition of treatment malignant tumor and preparation method thereof | |
| CN108743676B (en) | Application method of white peony root in preparation of medicine for treating hypertension | |
| CN102233084A (en) | Chinese medicinal composition for treating prostatitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |